Liu Zhao Bo

400,, 、,. 2006.9-2009.7 2016.9-2021.6 2018.8-2019.1 · 1、Z181100001018031,,,, 2018-2020; 2、LC19003,,,,2019-2022; SCI 5, 9, 2. 1、Liu Z, Fu Z, Li G, Lin D. Downstaging of Recurrent Advanced Hepatocellular Carcinoma After Lenvatinib Treatment: Opportunities or Pitfalls? A Case Report. Onco Targets Ther. 2020 Oct 13;13:10267-10273. 2、Liu Z, Wu M, Lin D, Li N. Des-gamma-carboxyprothrombin is a favorable biomarker for the early diagnosis of alfa-fetoprotein-negative hepatitis B virus-related hepatocellular carcinoma. J Int Med Res. 2020 Feb;48(2):300060520902575. 3、Wu M, Liu Z, Li X, Zhang A, Lin D, Li N. Analysis of potential key genes in very early hepatocellular carcinoma. World J Surg Oncol. 2019 May 1;17(1):77. doi: 10.1186/s12957-019-1616-6. 4、Wu M, Liu Z, Zhang A, Li N. Identification of key genes and pathways in hepatocellular carcinoma: A preliminary bioinformatics analysis. Medicine (Baltimore). 2019 5、Liu Z, Zang Y, Wang X, Li N, Lin D. Primary mucosa-associated lymphoid tissue lymphoma of the hilar bile duct resulting in fluctuant jaundice: A case report. Medicine (Baltimore). 2018 Oct;97(41):e12830. 6、,. [J].,2021,37(2):267-271. 7、,,,.PD-1 [J].,2021,12(4):445-449. 8、,,,,,,,. [J].,2013,12(3):186-190.,,. 3 [J].,2011,19(8):628-629. 9、《 》 2017.3. 10、《 》 2021.5